David Toung
Stock Analyst at Argus Research
(4.63)
# 887
Out of 4,988 analysts
344
Total ratings
65%
Success rate
9.5%
Average return
Main Sectors:
Stocks Rated by David Toung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Reiterated: Buy | $200 → $330 | $278.06 | +18.68% | 12 | Sep 16, 2026 | |
| ELV Elevance Health | Reiterated: Hold | n/a | $410.95 | - | 6 | Aug 20, 2026 | |
| HCA HCA Healthcare | Rated: Buy | $500 | $427.71 | +16.90% | 5 | Aug 7, 2026 | |
| PFE Pfizer | Reiterated: Buy | n/a | $27.66 | - | 13 | Aug 5, 2026 | |
| BSX Boston Scientific | Downgraded: Hold | n/a | $43.34 | - | 11 | Jul 30, 2026 | |
| DGX Quest Diagnostics | Reiterated: Buy | $175 → $260 | $246.45 | +5.50% | 3 | Jul 28, 2026 | |
| JNJ Johnson & Johnson | Rated: Buy | $210 → $300 | $269.99 | +11.12% | 14 | Jul 28, 2026 | |
| DHR Danaher | Rated: Buy | $230 | $211.81 | +8.59% | 6 | Jul 23, 2026 | |
| UNH UnitedHealth Group | Reiterated: Buy | $400 → $470 | $376.90 | +24.70% | 15 | Jul 17, 2026 | |
| SYK Stryker | Rated: Buy | $450 → $370 | $275.12 | +34.49% | 12 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $25 | $15.22 | +64.26% | 7 | Jun 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $310 | $320.71 | -3.34% | 3 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $266.42 | - | 5 | May 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $88.26 | - | 2 | May 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $610 → $560 | $651.45 | -14.04% | 10 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $115 | $92.13 | +24.82% | 18 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $290 → $180 | $180.94 | -0.52% | 16 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $280 → $400 | $308.78 | +29.54% | 19 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $110 → $95 | $64.13 | +48.14% | 3 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $88.84 | - | 3 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $386.22 | - | 21 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $65 → $68 | $72.37 | -6.04% | 10 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $570 → $775 | $874.65 | n/a | 15 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $150 | $102.61 | n/a | 12 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $6.30 | n/a | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $943.54 | n/a | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $450 → $520 | $393.33 | n/a | 8 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $150 | $95.36 | n/a | 15 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $665 → $770 | $1,152.93 | n/a | 9 | Feb 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $265 → $300 | $385.65 | n/a | 5 | Nov 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $115 → $125 | $146.87 | n/a | 10 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $75 | $150.11 | n/a | 11 | Jan 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $63.06 | n/a | 6 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $115 → $140 | $263.96 | n/a | 14 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $140.37 | n/a | 2 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $225.38 | n/a | 10 | Aug 27, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $215.50 | n/a | 1 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 → $19 | $4.70 | n/a | 3 | Oct 21, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $22.80 | n/a | 3 | Aug 15, 2016 |
Charles River Laboratories International
Sep 16, 2026
Reiterated: Buy
Price Target: $200 → $330
Current: $278.06
Upside: +18.68%
Elevance Health
Aug 20, 2026
Reiterated: Hold
Price Target: n/a
Current: $410.95
Upside: -
HCA Healthcare
Aug 7, 2026
Rated: Buy
Price Target: $500
Current: $427.71
Upside: +16.90%
Pfizer
Aug 5, 2026
Reiterated: Buy
Price Target: n/a
Current: $27.66
Upside: -
Boston Scientific
Jul 30, 2026
Downgraded: Hold
Price Target: n/a
Current: $43.34
Upside: -
Quest Diagnostics
Jul 28, 2026
Reiterated: Buy
Price Target: $175 → $260
Current: $246.45
Upside: +5.50%
Johnson & Johnson
Jul 28, 2026
Rated: Buy
Price Target: $210 → $300
Current: $269.99
Upside: +11.12%
Danaher
Jul 23, 2026
Rated: Buy
Price Target: $230
Current: $211.81
Upside: +8.59%
UnitedHealth Group
Jul 17, 2026
Reiterated: Buy
Price Target: $400 → $470
Current: $376.90
Upside: +24.70%
Stryker
Jul 9, 2026
Rated: Buy
Price Target: $450 → $370
Current: $275.12
Upside: +34.49%
Jun 17, 2026
Upgraded: Buy
Price Target: $25
Current: $15.22
Upside: +64.26%
Jun 2, 2026
Reiterated: Buy
Price Target: $310
Current: $320.71
Upside: -3.34%
May 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $266.42
Upside: -
May 21, 2026
Reiterated: Buy
Price Target: n/a
Current: $88.26
Upside: -
Apr 30, 2026
Reiterated: Buy
Price Target: $610 → $560
Current: $651.45
Upside: -14.04%
Apr 6, 2026
Reiterated: Buy
Price Target: $115
Current: $92.13
Upside: +24.82%
Mar 20, 2026
Rated: Buy
Price Target: $290 → $180
Current: $180.94
Upside: -0.52%
Mar 17, 2026
Reiterated: Buy
Price Target: $280 → $400
Current: $308.78
Upside: +29.54%
Mar 3, 2026
Rated: Buy
Price Target: $110 → $95
Current: $64.13
Upside: +48.14%
Dec 12, 2025
Reiterated: Buy
Price Target: n/a
Current: $88.84
Upside: -
Dec 8, 2025
Reiterated: Hold
Price Target: n/a
Current: $386.22
Upside: -
Nov 20, 2025
Rated: Buy
Price Target: $65 → $68
Current: $72.37
Upside: -6.04%
Aug 20, 2025
Rated: Buy
Price Target: $570 → $775
Current: $874.65
Upside: n/a
Apr 21, 2025
Reiterated: Buy
Price Target: $150
Current: $102.61
Upside: n/a
Mar 26, 2025
Reiterated: Hold
Price Target: n/a
Current: $6.30
Upside: n/a
Aug 15, 2024
Rated: Buy
Price Target: n/a
Current: $943.54
Upside: n/a
Jul 23, 2024
Reiterated: Buy
Price Target: $450 → $520
Current: $393.33
Upside: n/a
May 20, 2024
Upgraded: Buy
Price Target: $150
Current: $95.36
Upside: n/a
Feb 7, 2024
Reiterated: Buy
Price Target: $665 → $770
Current: $1,152.93
Upside: n/a
Nov 6, 2023
Reiterated: Buy
Price Target: $265 → $300
Current: $385.65
Upside: n/a
Jun 6, 2023
Reiterated: Buy
Price Target: $115 → $125
Current: $146.87
Upside: n/a
Jan 28, 2022
Upgraded: Buy
Price Target: $75
Current: $150.11
Upside: n/a
Nov 1, 2021
Downgraded: Hold
Price Target: n/a
Current: $63.06
Upside: n/a
Aug 5, 2021
Reiterated: Buy
Price Target: $115 → $140
Current: $263.96
Upside: n/a
Mar 10, 2021
Downgraded: Hold
Price Target: n/a
Current: $140.37
Upside: n/a
Aug 27, 2019
Downgraded: Hold
Price Target: n/a
Current: $225.38
Upside: n/a
Feb 16, 2018
Downgraded: Hold
Price Target: n/a
Current: $215.50
Upside: n/a
Oct 21, 2016
Reiterated: Buy
Price Target: $17 → $19
Current: $4.70
Upside: n/a
Aug 15, 2016
Reiterated: Hold
Price Target: n/a
Current: $22.80
Upside: n/a